Resveratrol-loaded folic acid-grafted dextran stearate submicron particles exhibits enhanced antitumor efficacy in non-small cell lung cancers

Materials Science and Engineering C

Volumn 72, Issue , 2017, Pages 185-191

  Zhao, Qing sheng ^a   Hu, Ling ling ^a   Wang, Zhi dong ^a   Li, Zhao pei ^b   Wang, Ai wen ^c   Liu, Jing ^d  

^a LINYI PEOPLE'S HOSPITAL   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c Lanling People's Hospital   (China)

^d THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Anticancer efficacy; Lung cancers; Polymeric micelles; Resveratrol

Indexed keywords

BIOLOGICAL ORGANS; CELL DEATH; CYTOLOGY; DEXTRAN; DISEASES; DRUG PRODUCTS; MICELLES; ORGANIC ACIDS; POLYMERS; RESVERATROL;

ANTI-TUMOR EFFICACY; ANTICANCER EFFICACY; CONTROLLED DRUG RELEASE; LUNG CANCER; NON SMALL CELL LUNG CANCER; POLYMERIC MICELLE; RECEPTOR INTERACTION; SUB-MICRON PARTICLES;

CELLS;

ANTINEOPLASTIC AGENT; CASPASE 3; DEXTRAN; FOLIC ACID; PROTEIN BAX; PROTEIN P53; RESVERATROL; STILBENE DERIVATIVE; TP53 PROTEIN, HUMAN;

A-549 CELL LINE; APOPTOSIS; CHEMISTRY; DRUG EFFECTS; DRUG RELEASE; HUMAN; LUNG TUMOR; METABOLISM; MITOCHONDRION; NON SMALL CELL LUNG CANCER; PARTICLE SIZE; PATHOLOGY;

A549 CELLS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; DEXTRANS; DRUG LIBERATION; FOLIC ACID; HUMANS; LUNG NEOPLASMS; MITOCHONDRIA; PARTICLE SIZE; STILBENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84995938149     PISSN: 09284931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.msec.2016.10.077     Document Type: Article

References (21)

1. [1] Jemal, A., Siegel, R., Xu, J., Ward, E., Cancer statistics 2010. CA Cancer J. Clin. 60 (2010), 277–300.
2. [2] Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J. Clin. 61 (2011), 69–90.
3. [3] Brodowicz, T., Krzakowski, M., Zwitter, M., Tzekova, V., Ramlau, R., Ghilezan, N., Ciuleanu, T., et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52 (2006), 155–163.
4. [4] Cosaert, J., Quoix, E., Platinum drugs in the treatment of nonsmall-cell lung cancer. Br. J. Cancer 87 (2002), 825–833.
5. [5] Jang, M., Cai, L., Udeani, G.O., Slowing, K.V., Thomas, C.F., Beecher, C.W., Fong, H.H., Farnsworth, N.R., Kinghorn, A.D., Mehta, R.G., Moon, R.C., Pezzuto, J.M., Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275 (1997), 218–220.
6. [6] Amri, A., et al. Administration of resveratrol: what formulation solutions to bioavailability limitations?. J. Control. Release 158 (2012), 182–193.
7. [7] Neves, A.R., et al. Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug delivery, and membrane interactions. Curr. Med. Chem. 19 (2012), 1663–1681.
8. [8] Mattarei, A., et al. Acetal derivatives as prodrugs of resveratrol. Mol. Pharm. 10 (2013), 2781–2792.
9. [9] Trela, B.C., Waterhouse, A.L., Resveratrol: isomeric molar absorptivities and stabilities. J. Agric. Food Chem. 44 (1996), 1253–1257.
10. [10] Miki, H., et al. Resveratrol induces apoptosis via ROS-triggered autophagy in human colon cancer cells. Int. J. Oncol. 40 (2012), 1020–1028.
11. [11] Summerlin, N., et al. Resveratrol nanoformulations: challenges and opportunities. Int. J. Pharm. 479 (2015), 282–290.
12. [12] Popat, A., et al. Programmable drug release using bioresponsive mesoporous silica submicron for site-specific oral drug delivery. Chem. Commun. 50 (2014), 5547–5550.
13. [13] Jambhrunkar, S., et al. Modulating in vitro release and solubility of griseofulvin using functionalized mesoporous silica submicron. J. Colloid Interface Sci. 434 (2014), 218–225.
14. [14] Jambhrunkar, S., et al. Mesoporous silica submicron enhance the cytotoxicity of curcumin. RSC Adv. 4 (2014), 709–712.
15. [15] Saxena, V., Delwar, M., Poloxamer 407/TPGS mixed micelles for delivery of gambogic acid to breast and multidrug-resistant cancer. Int. J. Nanomedicine 7 (2012), 713–772.
16. [16] Ramasamy, T., Kim, J., Choi, H.G., Yong, C.S., Kim, J.O., Novel dual drug-loaded block ionomer complex micelles for enhancing the efficacy of chemotherapy treatments. J. Biomed. Nanotechnol. 10 (2014), 1304–1312.
17. [17] Kim, J.O., Ramasamy, T., Yong, C.S., Nukolov, N.V., Bronich, T.K., Kabanov, A.V., Cross-linked polymeric micelles based on block ionomer complexes. Mendeleev Commun. 23 (2013), 179–186.
18. [18] Mozafari, M.R., et al. Encapsulation of food ingredients using nanoliposome technology. Int. J. Food Prop. 11 (2008), 833–844.
19. [19] Uma Devi, S.K., Ramasamy, T., Formulation and evaluation of chitosan microspheres of aceclofenac for colon-targeted drug delivery. Biopharm. Drug Dispos. 31 (2010), 407–427.
20. [20] Kerr, J.F., Winterford, C.M., Harmon, B.V., Apoptosis: its significance in cancer and cancer therapy. Cancer 73 (1994), 2013–2026.
21. [21] Higuchi, Y., Glutathione depletion-induced chromosomal DNA\fragmentation associated with apoptosis and necrosis. J. Cell. Mol. Med. 18 (2004), 45–64.